Article info
Case Report
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response
- ↵a joseph.vento{at}phhs.org
- ↵b aditi.mulgaonkar{at}utsouthwestern.edu
- ↵c layton.woolford{at}utsouthwestern.edu
- ↵d kien.nham{at}utsouthwestern.edu
- ↵e alana.christie{at}utsouthwestern.edu
- ↵f aditya.bagrodia{at}utsouthwestern.edu
- ↵g alberto.diazdeleon{at}utsouthwestern.edu
- ↵h raquibul.hannan{at}utsouthwestern.edu
- ↵i isaac.bowman{at}utsouthwestern.edu
- ↵j renee.mckay{at}utsouthwestern.edu
- ↵k payal.kapur{at}utsouthwestern.edu
- ↵l guiyang.hao{at}utsouthwestern.edu
- ↵m xiankai.sun{at}utsouthwestern.edu
- ↵n james.brugarolas{at}utsouthwestern.edu
Citation
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response
Publication history
- Received February 8, 2019
- Accepted May 2, 2019
- First published June 3, 2019.
Online issue publication
June 03, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.